A 1-year, Multicenter, Open-label Extension to CZOL446H2337 to Evaluate Safety and Efficacy of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids

Trial Profile

A 1-year, Multicenter, Open-label Extension to CZOL446H2337 to Evaluate Safety and Efficacy of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Male osteoporosis; Osteoporosis
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 16 Oct 2017 Planned End Date changed from 1 Apr 2019 to 15 Apr 2019.
    • 16 Oct 2017 Planned primary completion date changed from 1 Apr 2019 to 15 Apr 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top